Management of Adult Patients With Isocitrate Dehydrogenase‐Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro‐Oncology
Asia-Pacific Journal of Clinical Oncology · 2026-06 · 22 (3) · 392-403
DOI: 10.1111/ajco.70070 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 25.03.2026. Verfasst von Mark B Pinkham und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia. Hauptthemen laut MEDLINE: Glioma, Isocitrate Dehydrogenase, Brain Neoplasms. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Isocitrate dehydrogenase (IDH)‐mutant low‐grade and high‐grade gliomas are primary brain cancers with slower growth rates and longer survival than IDH‐wildtype counterparts. However, these tumors are fatal and because of the younger age of patients, result in significant morbidity and loss of productivity. Several management options are available at initial diagnosis for IDH‐mutant gliomas (including close surveillance, surgery, radiation therapy, chemotherapy and/or targeted therapies either alone or in combination), however, there is limited data about optimal timing and sequencing. When considering treatment, the risks associated with uncontrolled disease should be weighed against potential treatment‐associated toxicities given the expected long overall survival times for many patients. Preservation of cognition, neurological function and quality of life remain a priority. Treatment decisions should therefore be made in the context of a neuro‐oncology multidisciplinary team, and incorporating the patient's wishes and expectations. The management of recurrent IDH‐mutant glioma is not well defined. This expert position statement aims to provide an Australian perspective on the evidence base and available treatments for contemporaneous management of IDH‐mutant glioma in adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.
- College of Nursing and Health Sciences, Flinders University, Adelaide, South Australia, Australia.
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
- Faculty of Medicine and Health, University of New South Wales, Kensington, New South Wales, Australia.
- Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.
- Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.
Zitieren
APA
Pinkham, M. B., Sim, H. W., Jeffree, R. L., Lasocki, A., Legge, D. M., Saran, F., Satgunaseelan, L., & Gan, H. K. (2026). Management of Adult Patients With Isocitrate Dehydrogenase‐Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro‐Oncology. Asia-Pacific Journal of Clinical Oncology, 22(3), 392-403. https://doi.org/10.1111/ajco.70070
Vancouver
Pinkham MB, Sim HW, Jeffree RL, Lasocki A, Legge DM, Saran F, et al. Management of Adult Patients With Isocitrate Dehydrogenase‐Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro‐Oncology. Asia-Pacific Journal of Clinical Oncology. 2026;22(3):392-403. doi:10.1111/ajco.70070
BibTeX
@article{Pinkham2026,
author = {Pinkham, Mark B and Sim, Hao-Wen and Jeffree, Rosalind L and Lasocki, Arian and Legge, Dianne M and Saran, Frank and Satgunaseelan, Laveniya and Gan, Hui K},
title = {Management of Adult Patients With Isocitrate Dehydrogenase‐Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro‐Oncology},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
volume = {22},
number = {3},
pages = {392--403},
doi = {10.1111/ajco.70070}
}
EUVIMED